Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,635,888
  • Shares Outstanding, K 51,897
  • Annual Sales, $ 41,000 K
  • Annual Income, $ -68,360 K
  • 36-Month Beta 3.14
  • Price/Sales 40.29
  • Price/Cash Flow N/A
  • Price/Book 3.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.78
  • Number of Estimates 5
  • High Estimate -0.57
  • Low Estimate -0.89
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.34 +7.43%
on 02/07/19
37.47 -15.88%
on 01/16/19
-3.87 (-10.94%)
since 01/15/19
3-Month
22.22 +41.85%
on 12/21/18
40.99 -23.10%
on 12/03/18
-4.87 (-13.38%)
since 11/15/18
52-Week
22.22 +41.85%
on 12/21/18
73.90 -57.35%
on 05/24/18
-9.10 (-22.40%)
since 02/15/18

Most Recent Stories

More News
Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales

Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.

CELG : 90.69 (+0.01%)
LGND : 120.86 (-0.02%)
CRSP : 31.52 (+1.91%)
VRTX : 188.07 (+1.27%)
Interesting CRSP Put And Call Options For March 22nd

Investors in CRISPR Therapeutics AG saw new options begin trading today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain...

CRSP : 31.52 (+1.91%)
Is a Beat in Store for Vertex (VRTX) This Earnings Season?

On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

CELG : 90.69 (+0.01%)
CRSP : 31.52 (+1.91%)
VRTX : 188.07 (+1.27%)
ACAD : 23.25 (+6.02%)
Vertex Terminates COO Ian Smith on Code of Conduct Violation

Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.

CRSP : 31.52 (+1.91%)
VRTX : 188.07 (+1.27%)
ACOR : 14.30 (-8.10%)
ADRO : 4.05 (+10.05%)
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider,...

CRSP : 31.52 (+1.91%)
Market's Newfound Optimism Brings Another 1% Gain

Market's Newfound Optimism Brings Another 1% Gain

VIV : 12.97 (+0.46%)
BIDU : 170.06 (-2.31%)
LYV : 56.34 (+1.75%)
SLB : 44.95 (+1.84%)
AEM : 43.14 (+3.06%)
TRI : 52.96 (+0.51%)
WB : 64.28 (-1.91%)
TDC : 46.45 (+0.82%)
CRSP : 31.52 (+1.91%)
UBNT : 136.25 (+0.04%)
USAT : 3.66 (-0.27%)
NEM : 33.24 (+0.39%)
HES : 57.58 (+0.89%)
GRUB : 83.21 (+0.90%)
XBI : 86.59 (+2.13%)
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

CRSP : 31.52 (+1.91%)
VRTX : 188.07 (+1.27%)
EDIT : 20.08 (+1.11%)
NTLA : 13.99 (+0.72%)
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for...

CRSP : 31.52 (+1.91%)
VRTX : 188.07 (+1.27%)
CRSP February 22nd Options Begin Trading

Investors in CRISPR Therapeutics AG saw new options begin trading today, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain...

CRSP : 31.52 (+1.91%)
Christmas Comes a Day Late

Christmas Comes a Day Late

MTDR : 19.31 (+5.98%)
ECA : 6.90 (+5.50%)
CRSP : 31.52 (+1.91%)
PE : 18.73 (+1.52%)
TWTR : 31.23 (+0.87%)
ILMN : 299.82 (+2.51%)
BRY : 11.95 (+4.64%)
TQQQ : 50.03 (+1.19%)
XPER : 22.79 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 32.34
1st Resistance Point 31.93
Last Price 31.52
1st Support Level 30.96
2nd Support Level 30.40

See More

52-Week High 73.90
Fibonacci 61.8% 54.16
Fibonacci 50% 48.06
Fibonacci 38.2% 41.96
Last Price 31.52
52-Week Low 22.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar